Predictive validity of clinical variables in the "at risk" for psychosis population: International comparison with results from the North American Prodrome Longitudinal Study

A Thompson; B Nelson; A Yung

Journal article

Predictive validity of clinical variables in the "at risk" for psychosis population: International comparison with results from the North American Prodrome Longitudinal Study

A Thompson, B Nelson, A Yung

Schizophrenia Research | Published : 2011

DOI: 10.1016/j.schres.2010.09.024

Abstract

Background: There has been recent optimism with regard to improving the predictive validity of those individuals who develop a psychotic disorder from the "Ultra High Risk" (UHR) or putatively prodromal population using combinations of clinical variables. We aimed to test the recent results from a large collaborative consortium in an independent cohort from the PACE (Personal Assistance and Clinical Evaluation) clinic in Australia. Method: The North American Prodrome Longitudinal Study (NAPLS) consortium study reported 5 important clinical predictive variables within their US sample of UHR patients: genetic risk with functional decline; high unusual thought content score; high suspicion/para..

View full abstract

University of Melbourne Researchers

Andrew Thompson Author

Barnaby Nelson Author

Related Projects (1)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

Grants

Awarded by Eli Lilly and Company

Funding Acknowledgements

[ "Dr Yung was supported by National Health and Medical Research Council (NHMRC) Senior Research Fellowship, a NHMRC Program Grant (#566529) and by the Colonial Foundation Philanthropic Trust. Dr Nelson was supported by a Ronald Philip Griffith Fellowship and a NARSAD Young Investigator Award.", "Dr Yung has received investigator-initiated funding from Janssen Pharmaceuticals, and travel assistance from Astra-Zeneca, Bristol-Meyers Squibb, Janssen Pharmaceuticals and Eli Lilly, and has received honoraria from Janssen Pharmaceuticals and Eli Lilly. Dr Nelson has no competing interests. Dr Thompson has received investigator-initiated funding from Janssen Pharmaceuticals and from Astra-Zeneca. He holds a Neurosciences Research Grant sponsored by Pfizer pharmaceuticals." ]